T1	Participants 59 121	previously untreated advanced esophagogastric cancer patients.
T2	Participants 382 506	patients within an open label, randomized clinical phase II trial with advanced or metastatic gastric/esophagogastric cancer
T3	Participants 516 561	Previously untreated patients were randomized
T4	Participants 928 949	118 patients enrolled
T5	Participants 1580 1625	patients with advanced esophagogastric cancer
